HC Wainwright Issues Optimistic Forecast for MLYS Earnings

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) – Equities research analysts at HC Wainwright upped their Q1 2026 earnings estimates for shares of Mineralys Therapeutics in a research note issued on Monday, March 16th. HC Wainwright analyst M. Caufield now expects that the company will earn ($0.44) per share for the quarter, up from their prior estimate of ($0.52). HC Wainwright has a “Buy” rating and a $56.00 price target on the stock. The consensus estimate for Mineralys Therapeutics’ current full-year earnings is ($4.23) per share. HC Wainwright also issued estimates for Mineralys Therapeutics’ Q2 2026 earnings at ($0.50) EPS, Q3 2026 earnings at ($0.56) EPS, Q4 2026 earnings at ($0.63) EPS, FY2026 earnings at ($2.14) EPS, FY2027 earnings at ($2.40) EPS and FY2028 earnings at ($0.90) EPS.

A number of other research firms have also issued reports on MLYS. Stifel Nicolaus upped their target price on Mineralys Therapeutics from $45.00 to $52.00 and gave the company a “buy” rating in a research note on Friday, December 19th. Wall Street Zen raised Mineralys Therapeutics from a “sell” rating to a “hold” rating in a research report on Sunday. Jefferies Financial Group reissued a “hold” rating and issued a $30.00 price target on shares of Mineralys Therapeutics in a report on Friday, March 13th. Bank of America upped their price objective on Mineralys Therapeutics from $46.00 to $51.00 and gave the company a “buy” rating in a research report on Friday, March 13th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Mineralys Therapeutics in a research note on Thursday, January 22nd. Six analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Mineralys Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $49.14.

Mineralys Therapeutics Price Performance

Shares of MLYS opened at $23.90 on Wednesday. The firm has a 50 day simple moving average of $29.81 and a 200-day simple moving average of $35.71. Mineralys Therapeutics has a 1-year low of $10.44 and a 1-year high of $47.65. The stock has a market cap of $1.97 billion, a price-to-earnings ratio of -10.08 and a beta of 0.57.

Mineralys Therapeutics (NASDAQ:MLYS) last announced its earnings results on Thursday, March 12th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.57) by $0.17.

Hedge Funds Weigh In On Mineralys Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. Smartleaf Asset Management LLC increased its stake in shares of Mineralys Therapeutics by 198.2% during the 3rd quarter. Smartleaf Asset Management LLC now owns 1,017 shares of the company’s stock valued at $40,000 after acquiring an additional 676 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of Mineralys Therapeutics by 4.3% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 17,085 shares of the company’s stock worth $271,000 after acquiring an additional 702 shares during the last quarter. Navalign LLC acquired a new stake in shares of Mineralys Therapeutics in the fourth quarter worth approximately $33,000. Velan Capital Investment Management LP grew its holdings in Mineralys Therapeutics by 0.6% in the third quarter. Velan Capital Investment Management LP now owns 175,600 shares of the company’s stock valued at $6,659,000 after purchasing an additional 1,000 shares during the period. Finally, Royal Bank of Canada grew its holdings in Mineralys Therapeutics by 262.3% in the fourth quarter. Royal Bank of Canada now owns 1,529 shares of the company’s stock valued at $56,000 after purchasing an additional 1,107 shares during the period. 84.46% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Mineralys Therapeutics news, CEO Jon Congleton sold 16,236 shares of the stock in a transaction on Monday, January 12th. The stock was sold at an average price of $32.62, for a total transaction of $529,618.32. Following the transaction, the chief executive officer owned 639,151 shares of the company’s stock, valued at $20,849,105.62. This represents a 2.48% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, insider David Malcom Rodman sold 14,058 shares of the firm’s stock in a transaction on Friday, March 13th. The stock was sold at an average price of $26.26, for a total value of $369,163.08. Following the sale, the insider owned 76,140 shares in the company, valued at $1,999,436.40. This trade represents a 15.59% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 363,325 shares of company stock worth $12,298,347. 25.56% of the stock is owned by insiders.

Key Headlines Impacting Mineralys Therapeutics

Here are the key news stories impacting Mineralys Therapeutics this week:

• Positive Sentiment: HC Wainwright raised near‑term EPS for Q1–Q3 2026 and bumped its FY2026 estimate (now ($2.14)), while maintaining a “Buy” rating and $56 target — a vote of confidence that can support the stock. HC Wainwright note on MLYS
• Positive Sentiment: Company update: Mineralys reported 2025 results and said it advanced the regulatory review for its hypertension candidate (lorundrostat) — regulatory progress and clinical milestones are key upside catalysts for a clinical‑stage biotech. Mineralys reports 2025 results (MSN)
• Positive Sentiment: Institutional demand: recent 1Q filings show new/expanded positions from AQR, Goldman Sachs, Woodline and others — heavy institutional ownership (≈84%) can amplify moves and indicates investor interest. MLYS institutional holdings
• Neutral Sentiment: Analyst mix and consensus: despite several Buy ratings (6 Buys, 1 Hold, 1 Sell) the street still expects sizeable negative EPS this year (consensus ≈ -4.23), and the consensus target (~$49) remains well above the current price — signals both long‑term upside expectations and near‑term valuation risk. MarketBeat analyst summary
• Negative Sentiment: Insider selling: Director/insider David Malcom Rodman has sold multiple sizable blocks recently (including 6,348 shares on Mar 12), which can be read as near‑term selling pressure or profit‑taking. Insider trades alert
• Negative Sentiment: Offsetting estimate cuts: HC Wainwright trimmed FY2027 and FY2028 EPS forecasts slightly (and nudged Q4 2026 a touch weaker), showing some longer‑horizon uncertainty despite near‑term upgrades — these downgrades add caution for longer‑dated expectations. HC Wainwright detail

Mineralys Therapeutics Company Profile

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc and changed its name to Mineralys Therapeutics, Inc in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.